determined with significance in sparsely granulated tumors because of low basal levels. The results indicate that \g=a\-subunitproduction and release is characteristic of densely granulated somatotroph adenomas and that \g=a\-subunitis coregulated with growth hormone by adenohypophysiotropic substances; in contrast, \g=a\-subunitproduction by sparsely granulated somatotroph adenomas is rare and, when present, much lower in quantity. Our studies confirm that densely and sparsely granulated somatotroph adenomas represent separate entities. Sylvia L. Asa, Department of Pathology, Mount Sinai Hospital, 600 University Avenue, Toronto. Ontario.
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Clinical studies have documented elevated blood levels of a-subunit of glycoprotein hormones (a-SU) as well as growth hormone (GH) in a subset of acromegalic patients (1, 2) . Some have shown a parallel response of GH and a-SU secretion during stimulation with GHreleasing hormone (GRH) or thyrotropin-releasing hor¬ mone (TRH) or suppression by somatostatin (SRIH) or bromocriptine (1) (2) (3) (4) .
Morphologic studies of tumors in patients with acro¬ megaly have revealed that monomorphic somatotroph adenomas represent the largest group; by electronmicroscopy they are separated into two structurally distinct types: densely granulated and sparsely granu¬ lated somatotroph adenomas (5) . In addition to GH immunoreactivity, somatotroph adenomas often con¬ tain variable numbers of cells immunopositive for a-SU (6) (7) (8) (9) ; electron-microscopy occasionally discloses focal lactotroph or mammosomatotroph differentiation but provides no evidence of glycoprotein differentiation (5, 9) . Coexistence of GH and a-SU in the same cell and colocalization in the same secretory granule have been demonstrated by immunoelectron-microscopy (1, 10).
Release of a-SU in association with GH has been documented in vitro (1, 4, (11) (12) (13) (1, 4, (11) (12) (13) (14) . However, to our knowledge, the morphologic features of GH-secreting adenomas with a-SU release in vitro have only been analyzed in a group of plurihormonal adenomas of the acidophil cell line (13 
Results

Morphologic findings
By light microscopy the densely granulated tumors were predominantly acidophilic, whereas the sparsely granu¬ lated tumors were composed of chromophobic cells. Immunocytochemistry revealed the presence of GH in all adenomas. The immunoreactivity in densely granu¬ lated tumors was primarily diffuse throughout the cytoplasm of many cells (Fig. la) , whereas it was often juxtanuclear and less intense in the sparsely granulated adenoma cells (Fig. 2a) . Immunocytochemical studies to localize a-SU were not performed in two densely and one sparsely granulated adenomas (Tables 1 and 2 ). In addition to the immunopositivity for GH, 12 of 13 (Fig. 3) . The cells of sparsely granulated adenomas had charac¬ teristic morphology; they harbored irregularly ovoid nuclei with conspicuous nucleoli, well developed membranous cytoplasmic organelles and fibrous bodies consisting of spherically arranged filaments. The secretory granules were sparse, unevenly distributed and small, measuring 100-250 nm (Fig. 4) . (Fig. 5) . The effect of GRH on GH and a-SU was more prominent than that of TRH, whereas the effect of SRIH was comparable to that of bromocriptine.
While GH release by densely granulated adenomas responded to these compounds, changes in a-SU release could not be evaluated in 3 of 4 sparsely granulated adenomas owing to very low basal levels.
Other pituitary hormones, including PRL, TSH, FSH and LH, were detected at low levels in the initial culture media of 10 densely and 5 sparsely granulated adeno¬ mas; in all but 2 densely granulated adenomas, the levels of these hormones fell rapidly and they were undetec- (5, 18) . The reason for the marked similarity in age in our study is unclear.
Elevated serum a-SU levels have been reported in 9-28% of acromegalic patients (1, 3, 4) and were found in up to 37% of acromegaly patients in a recent study employing a sensitive monoclonal antibody radioimmu¬ noassay (2) . These data are comparable with the results of immunocytochemical studies, wherein a frequency as high as 55% of tumors contained a-SU in addition to GH immunoreactivity (6) (7) (8) (9) . SU release in culture media (1, 4, (11) (12) (13) Even though GH and a-SU represent structurally different molecules, normally originating from osten¬ sibly distinct adenohypophysial cell lines, they may both be released by adenomas of acromegalic patients. Inter¬ estingly, a-SU is also known to be localized in nontumorous somatotrophs (23, 24) . It has been shown that the transcription factor Pit-1 is required for acti¬ vation of GH and PRL genes (25, 26) and this factor is also localized in thyrotroph cells. Pit-1 expression may play a role in the regulation of a-SU production by somatotroph adenomas (9, 13) . However, it is conceiv¬ able that additional factors may be implicated in cytodifferentiation that would explain the expression of a-SU by GH producing cells.
